Literature DB >> 6092681

Characterization and myocarditic capabilities of coxsackievirus B3 variants in selected mouse strains.

C J Gauntt, P T Gomez, P S Duffey, J A Grant, D W Trent, S M Witherspoon, R E Paque.   

Abstract

Two variants of coxsackievirus B3 (CVB3) were compared with the original myocarditic parent variant (CVB3m) for myocarditic properties in several strains of mice. The ts1R variant produced little to no myocarditis in any of the nine mouse strains examined. The ts10R variant and CVB3m could be differentiated on the basis of the extent of myocarditis induced in mice of selected H-2b and H-2k haplotypes and in the female versus the male responses of two other inbred strains. Virus quantities recovered from the hearts of myocarditic mice did not correlate with the extent of disease. The three variants could not be differentiated on the basis of: (i) rate and extent of adsorption to heart tissue homogenates, (ii) kinetic neutralization rates with antiserum directed against CVB3m, (iii) 125I labeling of surface regions of polypeptides on purified particles, or (iv) rates of heat inactivation of infectivity at 50 degrees C. These data suggest that differences in pathogenicity cannot be attributed to major alterations in capsid polypeptides. Oligonucleotide fingerprint maps of T1 RNase digests of the genomes of purified particles of the three CVB3 variants showed distinct differences. Thus, the extent of myocarditis induced by CVB3 variants in a mouse model is affected by some subtle expression of the genome, presumably not involving capsid polypeptides, as well as by the haplotype and sex of a given mouse host species.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6092681      PMCID: PMC254563     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  42 in total

1.  Oligonucleotide mapping of picornavirus RNAs by two-dimensional electrophoresis.

Authors:  D P Frisby; C Newton; N H Carey; P Fellner; J F Newman; T J Harris; F Brown
Journal:  Virology       Date:  1976-06       Impact factor: 3.616

Review 2.  Coxsackie virus myopericarditis. A microbiological and clinical review.

Authors:  S Z Hirschman; G S Hammer
Journal:  Am J Cardiol       Date:  1974-08       Impact factor: 2.778

Review 3.  Virus myocardiopathy.

Authors:  A M Lerner; F M Wilson
Journal:  Prog Med Virol       Date:  1973

4.  Post-coxsackie virus B3 myocardiopathy in mice.

Authors:  S M Feinstone; G T Hensley; M W Rytel
Journal:  Proc Soc Exp Biol Med       Date:  1973-10-01

5.  Involvement of T lymphocytes in the pathogenesis of coxsackie virus B3 heart disease.

Authors:  J F Woodruff; J J Woodruff
Journal:  J Immunol       Date:  1974-12       Impact factor: 5.422

Review 6.  The role of viruses in the production of heart disease.

Authors:  G E Burch; T D Giles
Journal:  Am J Cardiol       Date:  1972-02       Impact factor: 2.778

7.  Letter: A possible association between paralytic poliomyelitis and multiple sclerosis.

Authors:  P J Morris; M C Pietsch
Journal:  Lancet       Date:  1973-10-13       Impact factor: 79.321

8.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

9.  A relation between HLA antigens and clinical features in patients with acquired valvular heart disease.

Authors:  C Ward; K Gelsthorpe; R W Doughty
Journal:  Br Med J       Date:  1976-06-19

10.  Functional subclasses of T-lymphocytes bearing different Ly antigens. I. The generation of functionally distinct T-cell subclasses is a differentiative process independent of antigen.

Authors:  H Cantor; E A Boyse
Journal:  J Exp Med       Date:  1975-06-01       Impact factor: 14.307

View more
  21 in total

1.  Detection of enteroviral RNA in idiopathic dilated cardiomyopathy and other human cardiac tissues.

Authors:  L M Weiss; X F Liu; K L Chang; M E Billingham
Journal:  J Clin Invest       Date:  1992-07       Impact factor: 14.808

Review 2.  Gender differences in autoimmunity associated with exposure to environmental factors.

Authors:  K Michael Pollard
Journal:  J Autoimmun       Date:  2011-12-03       Impact factor: 7.094

3.  In situ immune autoradiographic identification of cells in heart tissues of mice with coxsackievirus B3-induced myocarditis.

Authors:  E K Godeny; C J Gauntt
Journal:  Am J Pathol       Date:  1987-11       Impact factor: 4.307

4.  Nitric oxide inhibition of coxsackievirus replication in vitro.

Authors:  C Zaragoza; C J Ocampo; M Saura; A McMillan; C J Lowenstein
Journal:  J Clin Invest       Date:  1997-10-01       Impact factor: 14.808

5.  Coxsackievirus B3-induced myocarditis: differences in the immune response of C57BL/6 and Balb/c mice.

Authors:  Carola Leipner; Katja Grün; Ilka Schneider; Brigitte Glück; Holger H Sigusch; Axel Stelzner
Journal:  Med Microbiol Immunol       Date:  2003-10-31       Impact factor: 3.402

6.  The role of CD8+ T lymphocytes in coxsackievirus B3-induced myocarditis.

Authors:  A Henke; S Huber; A Stelzner; J L Whitton
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

7.  Susceptibility and resistance to poliovirus-induced paralysis of inbred mouse strains.

Authors:  B Jubelt; S L Ropka; S Goldfarb; C Waltenbaugh; R P Oates
Journal:  J Virol       Date:  1991-02       Impact factor: 5.103

8.  Detection of Coxsackievirus B3 RNA in myocardial tissues by the polymerase chain reaction.

Authors:  L M Weiss; L A Movahed; M E Billingham; M L Cleary
Journal:  Am J Pathol       Date:  1991-02       Impact factor: 4.307

9.  Coxsackievirus B3-induced myocarditis: perforin exacerbates disease, but plays no detectable role in virus clearance.

Authors:  J R Gebhard; C M Perry; S Harkins; T Lane; I Mena; V C Asensio; I L Campbell; J L Whitton
Journal:  Am J Pathol       Date:  1998-08       Impact factor: 4.307

10.  Characterization of a murine model of myocarditis induced by a reactivated coxsackievirus B3.

Authors:  H Zhang; G E Yousef; X Ouyang; L C Archard
Journal:  Int J Exp Pathol       Date:  1994-04       Impact factor: 1.925

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.